- HETEROCYCLIC LSF INHIBITORS AND THEIR USES
-
The present invention is directed to heterocyclic SV40 Factor (LSF) inhibitors and their uses. In some implementations, the present invention discloses small-molecule compounds of Formula (I). In some implementations, the compounds of Formula (I) are used
- -
-
-
- Class of large ring heterocyclic compound restraining HCV and manufacturing and uses thereof
-
The invention relates to a class of compounds that inhibit HCV. The compounds are represented by Formula A. The invention also relates to preparation and pharmaceutical use of the compounds.
- -
-
-
- Benzimidazole compound
-
An object of the present invention is to provide a novel chemical compound useful as a therapeutic or prophylactic agent for acid-related diseases, having an excellent inhibitory effect against gastric acid secretion, an excellent effect of maintaining the inhibitory effect against gastric acid secretion, thereby maintaining intragastric pH high for a long time, and having more safety and appropriate physicochemical stability. Provided is a compound represented by where R1 and R3 may be the same or different and each represent a hydrogen atom or a C1-C6 alkyl group; R2 represents (5,5-dimethyl-1,3-dioxan-2-yl)methoxy group, 5,7-dioxaspiro[2.5]oct-6-ylmethoxy group, 1,5,9-trioxaspiro[5.5]undec-3-ylmethoxy group, or (2,2-dimethyl-1,3-dioxan-5-yl)methoxy group; R4, R5, R6 and R7 represent a hydrogen atom, halogen atom, C1-C6 alkyl group, C1-C6 haloalkyl group, C1-C6 alkoxy group or C1-C6 haloalkoxy group; and W1 represents a single bond, methylene or ethylene group, a salt thereof or a solvate of these.
- -
-
Page/Page column 90
(2008/06/13)
-
- Inhibitors or bone reabsorption and antagonists of vitronectin receptors
-
Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors The present invention relates to 5-membered ring heterocycles of the formula I, in which E, F, G, W, Y and Z have the meaning given in the patent claims, to their preparation a
- -
-
-
- Structure-activity relationships of alkyl- and alkoxy-substituted 1,4- dihydroquinoxaline-2,3-diones: Potent and systemically active antagonists for the glycine site of the NMDA receptor
-
We report on a series of alkyl- and alkoxy-substituted 1,4- dihydroquinoxaline-2,3-diones (QXs), prepared as a continuation of our structure-activity relationship (SAR) study of QXs as antagonists for the glycine site of the N-methyl-D-aspartate (NMDA) re
- Cai, Sui Xiong,Kher, Sunil M.,Zhou, Zhang-Lin,Ilyin, Victor,Espitia, Stephen A.,Tran, Minhtam,Hawkinson, Jon E.,Woodward, Richard M.,Weber, Eckard,Keana, John F. W.
-
p. 730 - 738
(2007/10/03)
-